Men’s Collection

Tesamorelin – 10mg, BPC-157 & TB-500 “Wolverine”,  Retatrutide – 10mg.

The ultimate men’s research collection featuring three of our most popular compounds.

Tesamorelin – 10mg.

Tesamorelin is a chemically modified growth hormone-releasing hormone (GHRH) analog composed of 44 amino acids. It is a trans-3-hexanoic acid version of natural GHRH, where the trans-3-hexanoic acid group is added to the N-terminus while the C-terminus is amidated and acetylated. This structural modification may increase its stability and extend its half-life compared to endogenous GHRH. Tesamorelin appears to mediate the positive influence of GHRH and other GHRH analogs such as GRF(1-29), CJC-1295, and Sermorelin by maintaining the physiological activity of GHRH without disrupting the natural pulsatile rhythm of growth hormone release. Research suggests that Tesamorelin may potentially stimulate growth hormone secretion from anterior pituitary somatotrophs through GHRH receptor binding, which initiates intracellular signaling cascades involving G-protein activation, cAMP production, and downstream gene transcription associated with growth hormone synthesis. Its mechanism of action positions it as a research compound of interest in studies examining growth hormone pathways, visceral adiposity, and body composition modulation.

BPC-157 & TB-500 “Wolverine”

Based on Tβ4 research, TB-500 has been suggested to exert potential action on cellular motility via elevating the levels of actin proteins. More specifically it has been posited to regulate the cellular actin-cytoskeleton and cellular migration by sequestering G-actin. TB-500 has a distinct amino acid segment [(17)LKKTETQ(23)] which is hypothesized to be responsible for actin binding and potentially enhancing cellular motility. This in turn may exhibit positive action on wound healing processes. TB-500 also seems to amplify the presence of microRNA-146a (miR-146a), which may act as a repressive regulator for certain cellular signaling routes such as those related to the activity of two inflammation-related cytokines called L-1 receptor-linked kinase 1 (IRAK1) and tumor necrosis factor receptor-linked factor 6 (TRAF6). This suggestion was further insisted as a potential mechanism of TB-500 by the authors of the research study, who also commented that “transfection of anti-miR-146a nucleotides reversed the inhibitory effect of Tβ4 on IRAK1 and TRAF6.” Thus, TB-500 also appears to potentially work for healing by exerting anti-inflammatory action.

BPC-157 peptide has been suggested to exert some action via various processes encompassing nitric oxide production, control of cells pertinent to tissue restoration, growth elements, and inflammatory responses. It is conceivable that BPC-157 may exhibit some engagement with the NO mechanism, possibly providing a safeguard for the endothelium and perhaps encouraging angiogenic behaviors by fostering the development of new circulatory routes. Researchers suggest there is a chance it may boost the expression of the early growth response 1 gene, which may play a role in producing cytokines and growth stimuli, and possibly aid in the initial assembly of the extracellular framework, inclusive of collagen. It is worth highlighting that BPC-157’s relation with nerve growth factor 1-A binding protein-2 may exert inhibitory action on specific elements. As a result, new tissues composed of collagen may be formed, thereby possibly enhancing the healing of wounds more rapidly.

As both TB-500 and BPC-157 peptides appear to exhibit similar pharmacological potential, when blended together, the potential action of both may be maximized – what would otherwise occur with one peptide, might occur at a better, faster rate when combined.

Retatrutide – 10mg.

Retatrutide (LY3437943) is a 39-amino-acid synthetic triple receptor agonist engineered from a GIP peptide backbone. It simultaneously activates the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR) — three pivotal receptors involved in metabolic regulation. Its structure incorporates non-coded residues (Aib2, Aib20, α-MeLeu13) and a C20 fatty diacid conjugation to enhance stability and extend systemic presence through albumin binding. In preclinical models, Retatrutide has been shown to induce cAMP accumulation, decrease plasma glucose levels, and reduce body weight, calorie intake, and fat mass in a dose-dependent manner. Phase 2 clinical data demonstrated significant improvements in glycemic control and robust reductions in bodyweight with a safety profile consistent with existing GLP-1 receptor agonist therapies. Retatrutide represents a next-generation approach in metabolic research, building upon the dual-agonist framework established by compounds like tirzepatide.